Fiche société
Candid Therapeutics
Traitements, essais et publications liés.
Traitements3programmes
Essais2liés
Publications0liées
SourceDBlocale
Traitements
3| Molécule | Indication / population | Phase | Objectif | Pays | Résultat |
|---|---|---|---|---|---|
| CizutamigThe purpose of this study is to assess the safety, tolerability, PK, PD, immunogenicity, and preliminary clinical activity of Cizutamig in patients with Systemic Lupus Erythematosus | Lupus, Myasthénie | Phase 1 | À vérifier | China | À vérifier |
| CizutamigThe purpose of this study is to assess the safety, tolerability, PK, PD, immunogenicity, and preliminary clinical activity of Cizutamig in patients with Systemic Lupus Erythematosus | Lupus | Phase 1 | À vérifier | China | À vérifier |
| CizutamigThe purpose of this study is to assess the safety, tolerability, PK, PD, immunogenicity, and preliminary clinical activity of Cizutamig in patients with Systemic Lupus Erythematosus | Myasthénie | Phase 1 | À vérifier | China | À vérifier |
Essais cliniques
2| Molécule | Indication / population | Phase | NCT | Titre | Statut |
|---|---|---|---|---|---|
| Cizutamig | Myasthénie | Phase 1 | NCT07215650 | Clinical Study of Cizutamig in Generalized Myasthenia Gravis (gMG) | RECRUITING |
| Cizutamig | Lupus | Phase 1 | NCT07215663 | Clinical Study of Cizutamig in Systemic Lupus Erythematosus | RECRUITING |
Publications
0| Molécule | Indication / population | Titre | Journal | Date |
|---|---|---|---|---|
| Aucune publication. | ||||